Equities
  • Price (USD)49.47
  • Today's Change-0.14 / -0.28%
  • Shares traded100.00
  • 1 Year change-3.38%
  • Beta--
Data delayed at least 15 minutes, as of Dec 02 2022 14:30 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
BDX:NYQ since
announced
Transaction
value
MedKeeper LLCDeal completed28 Jul 202228 Jul 2022Deal completed1.59%93.00m
Parata Systems LLCDeal completed06 Jun 202206 Jun 2022Deal completed-1.63%1.53bn
Cytognos SLDeal completed31 Jan 202231 Jan 2022Deal completed-2.94%--
Scanwell Health IncDeal completed21 Dec 202121 Dec 2021Deal completed-1.66%--
Tissuemed LtdDeal completed09 Dec 202109 Dec 2021Deal completed0.72%--
Data delayed at least 15 minutes, as of Dec 02 2022 14:30 GMT.

Institutional shareholders

61.77%Per cent of shares held by top holders
HolderShares% Held
Capital Research & Management Co. (World Investors)as of 30 Sep 20225.65m16.37%
American Century Investment Management, Inc.as of 30 Sep 20224.06m11.78%
T. Rowe Price Associates, Inc. (Investment Management)as of 30 Sep 20223.79m11.00%
BlackRock Fund Advisorsas of 30 Sep 20222.45m7.10%
Manulife Investment Management (US) LLCas of 30 Sep 20221.56m4.53%
Columbia Management Investment Advisers LLCas of 30 Sep 20221.12m3.25%
Newton Investment Management North America LLCas of 30 Sep 2022790.86k2.29%
Everett Harris & Co.as of 30 Sep 2022643.78k1.87%
BlackRock Advisors LLCas of 30 Sep 2022631.44k1.83%
Franklin Advisers, Inc.as of 30 Sep 2022606.82k1.76%
More ▼
Data from 30 Sep 2022 - 30 Sep 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.